GoAI
Get started
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

AKBA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.9066

−$0.0128 · -1.39%

Aug 21, 4:00 PM ET

AKBA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

82

Deep Value

Momentum

45

Neutral

Sentiment

49

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
John Butler
Listed since
Mar 20, 2014
Employees
194

Market position

Day range

Current $0.9066

52-week range

Current $0.9066

Open
$0.9147
Previous close
$0.9194
Volume
6.45M
1.32× average
Average volume
4.88M
Average daily volume
Market cap
243.2M USD
Beta
0.24
Market reference 1
50-day average
$1.1418
-20.60% below average
200-day average
$1.3407
-32.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
445.48M USD
P/E (TTM)
-8.39×
P/B (TTM)
9.77×
P/S (TTM)
1.11×
EV / EBITDA
20.5×
Earnings yield
-1.29%
Free cash flow yield
16.42%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
79.48%
Operating margin
-6.91%
Net margin
-13.54%
Return on equity
-16.39%
Return on assets
-1.42%
Return on invested capital
9.26%

Financial health

Debt / equity
2.16×
Current ratio
1.13×
Altman Z-score
-5.69
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends115%25%-66%-156%Gross margin, FY2021: 61.50%Gross margin, FY2022: 92.31%Gross margin, FY2023: 61.90%Gross margin, FY2024: 60.56%Gross margin, FY2025: 83.29%Operating margin, FY2021: -124.97%Operating margin, FY2022: -27.62%Operating margin, FY2023: -23.77%Operating margin, FY2024: -31.51%Operating margin, FY2025: 9.95%Net margin, FY2021: -133.25%Net margin, FY2022: -32.22%Net margin, FY2023: -26.68%Net margin, FY2024: -43.33%Net margin, FY2025: -2.26%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.50%. Gross margin FY2022 92.31%. Gross margin FY2023 61.90%. Gross margin FY2024 60.56%. Gross margin FY2025 83.29%. Operating margin FY2021 -124.97%. Operating margin FY2022 -27.62%. Operating margin FY2023 -23.77%. Operating margin FY2024 -31.51%. Operating margin FY2025 9.95%. Net margin FY2021 -133.25%. Net margin FY2022 -32.22%. Net margin FY2023 -26.68%. Net margin FY2024 -43.33%. Net margin FY2025 -2.26%.

Income trends

Revenue

236.2M USD+47.46%

Operating income

23.5M USD+73.97M USD

Net income

−5.35M USD+92.30%
Income trends across reported periods349.93M USD120.13M USD−109.67M USD−339.47M USDRevenue, FY2021: 211.65M USDRevenue, FY2022: 292.48M USDRevenue, FY2023: 194.62M USDRevenue, FY2024: 160.18M USDRevenue, FY2025: 236.2M USDOperating income, FY2021: −264.5M USDOperating income, FY2022: −80.78M USDOperating income, FY2023: −46.26M USDOperating income, FY2024: −50.47M USDOperating income, FY2025: 23.5M USDNet income, FY2021: −282.02M USDNet income, FY2022: −94.23M USDNet income, FY2023: −51.93M USDNet income, FY2024: −69.41M USDNet income, FY2025: −5.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 211.65M USD. Revenue FY2022 292.48M USD. Revenue FY2023 194.62M USD. Revenue FY2024 160.18M USD. Revenue FY2025 236.2M USD. Operating income FY2021 −264.5M USD. Operating income FY2022 −80.78M USD. Operating income FY2023 −46.26M USD. Operating income FY2024 −50.47M USD. Operating income FY2025 23.5M USD. Net income FY2021 −282.02M USD. Net income FY2022 −94.23M USD. Net income FY2023 −51.93M USD. Net income FY2024 −69.41M USD. Net income FY2025 −5.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue236.2M USD160.18M USD194.62M USD292.48M USD211.65M USD
Cost of goods sold39.46M USD63.18M USD74.15M USD22.5M USD81.49M USD
Gross profit196.73M USD97M USD120.47M USD269.99M USD130.16M USD
Research and development62.36M USD37.65M USD63.08M USD165.99M USD147.85M USD
Selling, general, and administrative107.48M USD106.55M USD100.23M USD138.6M USD174.14M USD
Operating expenses173.24M USD147.48M USD166.73M USD350.77M USD394.66M USD
Interest expense24.18M USD18.19M USD6.03M USD15.69M USD19.94M USD
Depreciation and amortization1.27M USD37.5M USD37.63M USD37.7M USD37.97M USD
Operating income23.5M USD−50.47M USD−46.26M USD−80.78M USD−264.5M USD
Net income−5.35M USD−69.41M USD−51.93M USD−94.23M USD−282.02M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+11.53%
11 comparable reports
Latest EPS result
-0.02
Estimate -0.04 · Beat by 52.38%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.070-0.07-0.14Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.1, estimate -0.05, surprise -100.00%, Miss. Q2 2025, reported May 8, 2025: actual 0.03, estimate -0.03, surprise +200.00%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.001, estimate -0.02, surprise +104.55%, Beat. Q4 2025, reported Nov 10, 2025: actual 0.002, estimate -0.06, surprise +103.28%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.05, estimate -0.03, surprise -66.67%, Miss. Q2 2026, reported May 7, 2026: actual -0.03, estimate -0.01, surprise -200.00%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.02, estimate -0.042, surprise +52.38%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates64.97M54.95M44.93M34.92MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 46.5M USD, estimate 37.41M USD, surprise +24.28%, Beat. Q2 2025, reported May 8, 2025: actual 57.34M USD, estimate 50.8M USD, surprise +12.87%, Beat. Q3 2025, reported Aug 7, 2025: actual 62.47M USD, estimate 47.89M USD, surprise +30.45%, Beat. Q4 2025, reported Nov 10, 2025: actual 58.77M USD, estimate 48.37M USD, surprise +21.49%, Beat. Q1 2026, reported Feb 26, 2026: actual 57.62M USD, estimate 46.09M USD, surprise +25.01%, Beat. Q2 2026, reported May 7, 2026: actual 53.54M USD, estimate 51.67M USD, surprise +3.63%, Beat. Q3 2026, reported Aug 5, 2026: actual 49.13M USD, estimate 48.85M USD, surprise +0.56%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 46.55M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.00

10.30% upside
Past 12 months12-month forecastHigh $1.00Average $1.00Low $1.00

Recent analyst actions

4 institutions
Leerink PartnersdowngradeOutperformMarket Perform

AKBA news

seekingalpha.com

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.

Read source
marketbeat.com

Akebia Therapeutics Q2 Earnings Call Highlights

Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline.

Read source
globenewswire.com

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial…

Read source
globenewswire.com

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired…

Read source
globenewswire.com

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the…

Read source

AKBA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AKBA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.44M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.15M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.18M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.91M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.71M
Weight
0.03%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.16M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
1M
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research AKBA

research.disclaimer